Aqueous Humour Cytokine Changes with Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema

References

• Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1–9.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The wisconsin epidemiologic study of diabtic retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16.
   PubMed Web of Science ®Google Scholar
• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909.
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358. doi:10.1016/j.preteyeres.2011.05.002.
   PubMed Web of Science ®Google Scholar
• Dong N, Xu B, Chu L, et al. Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema. PLoS One. 2015;10(4):e0125329. doi:10.1371/journal.pone.0125329.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Jonas RA, Neumaier M, et al. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32:2150–2157. doi:10.1097/IAE.0b013e3182576d07.
   PubMed Web of Science ®Google Scholar
• Kwon J, Jee D. Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment. PLoS One. 2018;13(9):e0203408.  doi:10.1371/journal.pone.0203408.
   Web of Science ®Google Scholar
• Fogli S, Mogavero S, Egan CG, et al. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res. 2016;103:149–157. doi:10.1016/j.phrs.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Bandello F, Loewenstein A. Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol. 2015;16(9):1321–1335. doi:10.2147/OPTH.S79948.
   Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80–86. doi:10.1167/iovs.10-5285.
   PubMed Web of Science ®Google Scholar
• Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686–694. doi:10.1016/j.ajo.2011.03.033.
   PubMed Web of Science ®Google Scholar
• Shiraya T, Kato S, Araki F, et al. Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema. PLoS One. 2017;12(3):e0174340. doi:10.1371/journal.pone.0174340.
   PubMed Web of Science ®Google Scholar
• Lim SW, Bandala-Sanchez E, Kolic M, et al. The influence of intravitreal ranibizumab on inflammation-associated cytokine concentrations in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59:5382–5390. doi:10.1167/iovs.17-23325.
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, D’Aloisio R, Di Nicola M, et al. Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal a ibercept for diabetic macular edema. Sci Rep. 2018;8(1):16548. doi:10.1038/s41598-018-35036-9.
   PubMedGoogle Scholar
• Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial. Am J Ophthalmol. 2016;168:13–23. doi:10.1016/j.ajo.2016.04.017.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923. doi:10.1097/IAE.0b013e318206d18c.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort RJ, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024.
   PubMed Web of Science ®Google Scholar
• Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):463–473. doi:10.1007/s00417-016-3472-1.
   PubMed Web of Science ®Google Scholar
• Bellocq D, Akesbi J, Matonti F, et al. The pattern of recurrence in diabetic macular edema treated by dexamethasone implant: the PREDIAMEX study. Ophthalmol Retina. 2018;2(6):567–573. doi:10.1016/j.oret.2017.10.016.
   PubMedGoogle Scholar
• Wilkinson CP, Ferris F, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–1682. doi:10.1016/S0161-6420(03)00475-5.
   PubMed Web of Science ®Google Scholar
• Wu L, Fernandez-Loaiza P, Sauma J, et al. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4(6):290–294. doi:10.4239/wjd.v4.i6.290.
   PubMedGoogle Scholar
• Dong N, Xu B, Wang B, et al. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19:1734–1746.
   PubMed Web of Science ®Google Scholar
• Roh MI, Kim HS, Song JH, et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology. 2009;116(1):80–86. doi:10.1016/j.ophtha.2008.09.036.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema. Ophthalmology. 2014;121(12):2473–2478. doi:10.1016/j.ophtha.2014.07.002.
   PubMed Web of Science ®Google Scholar
• Rangasamy S, McGuire PG, Franco Nitta C, et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One. 2014;20(9):e108508. doi:10.1371/journal.pone.0108508.
   Google Scholar
• Kim JY, Jeong YJ, Park SP. Different concentrations of aqueous cytokines according to diabetic macular edema patterns as determined optical coherence tomography. J Clin Exp Ophthalmol. 2014;5(6):380. doi:10.4172/2155-9570.1000380.
   Google Scholar
• Kim M, Kim Y, Lee SJ. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema. Indian J Ophthalmol. 2015;63(4):312–317. doi:10.4103/0301-4738.158069.
   PubMed Web of Science ®Google Scholar
• Rezar-Dreindl S, Eibenberger K, Pollreisz A, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol. 2017;95(2):e119–e27. doi:10.1111/aos.13152.
   PubMed Web of Science ®Google Scholar
• Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, et al. Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Invest Ophthalmol Vis Sci. 2019;60:1336–1343. doi:10.1167/iovs.18-26215.
   PubMed Web of Science ®Google Scholar
• Figueras-Roca M, Molins B, Sala- Puigdollers A, et al. Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema. PLoS One. 2017;12(3):e0173865. doi:10.1371/journal.pone.0173865.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38:1361–1370. doi:10.1097/IAE.0000000000001690.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-il6-r tocilizumab in refractory and non-infectious uveitic cystoid macular edema. Multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94. doi:10.1016/j.ajo.2018.12.019.
   PubMed Web of Science ®Google Scholar